Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Gilead's Offer for Pharmasset Follows Closely on the Heels of Roche's Bid for Anadys: Could Achillion and Inhibitex Be Next?

Gilead (GILD) is certainly paying up for Pharmasset with its offer to buy the company at $137 per share ($11…
Read more…